News

Second death linked to Sarepta Therapeutics treatment leaves Duchenne muscular dystrophy community reeling, ... His own 10-year-old son, Konner, received the treatment, called Elevidys, ...
Capricor Therapeutics (CAPR) on Friday said the U.S. Food and Drug Administration (FDA) has refused to approve its lead cell ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...
In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...
The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...
The one-time treatment is approved for children with a genetic variant of Duchenne’s muscular dystrophy, ... Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting ...
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.
Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ...
Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.